Join Our Network
Pharmacy / Merchant
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023
Eskayef Pharmaceuticals Ltd. · IV Infusion
/ 65 mcg vial
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.
Difelikefalin Acetate IV Infusion is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis.
Difelikefalin Acetate is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.
Recommended dosage is 0.5 mcg/kg. Administer by intravenous bolus injection into the venous line of the dialysis circuit at the end of each hemodialysis treatment। Do not mix or dilute Difelikefalin Acetate prior to administration। Administer within 60 minutes of syringe preparation. If a regularly scheduled hemodialysis treatment is missed, resume Difelikefalin Acetate at the end of the next hemodialysis treatment.PEDIATRIC USE: The safety and effectiveness of Difelikefalin Acetate in pediatric patients have not been established.GERIATRIC USE: No overall differences in safety or effectiveness of Difelikefalin Acetate have been observed between patients 65 years of age and older and young adult subjects.
No clinical studies evaluating the drug interaction potential of Difelikefalin Acetate were conducted.
The most common adverse reactions are diarrhea, dizziness, nausea, gait disturbances, including falls, hyperkalemia, headache, somnolence, and mental status change.
The limited human data on use of Difelikefalin Acetate in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. There are no data regarding the presence of Difelikefalin Acetate in human milk or effects on the breastfed infant or on milk production.
Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances: Dizziness, somnolence, mental status changes, and gait disturbances, including falls, have occurred in patients taking Difelikefalin Acetate and may subside over time with continued treatment. Concomitant use of centrally-acting depressant medications, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with Difelikefalin Acetate.Risk of Driving and Operating Machinery: Dizziness, somnolence, and mental status changes have occurred in patients taking Difelikefalin Acetate. Difelikefalin Acetate may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of Difelikefalin Acetate on a patient’s ability to drive or operate machinery is known.
Do not store above 25°C temperature. Keep away from light and wet place. Keep out of reach of children.